GOVX
GeoVax Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.50
−1.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 2.5M | 4.0M | — | 81.5K |
| Cost of Revenue | 8.9M | 18.1M | 95.4K | 20.7M | 9.1M |
| Gross Profit | (8.9M) | (15.6M) | 3.9M | (20.7M) | (9.0M) |
| Operating Expenses | |||||
| R&D Expense | 15.1M | 18.1M | 23.7M | 20.7M | 9.1M |
| SG&A Expense | 5.5M | 6.0M | 5.4M | 5.9M | 5.0M |
| General & Admin Expense | 5.5M | 6.0M | 5.4M | 6.0M | 5.0M |
| Selling & Marketing Expense | — | — | — | (74.2K) | — |
| Other Expenses | (8.9M) | (18.1M) | (95.4K) | (20.6M) | (9.1M) |
| Total Operating Expenses | 11.6M | 6.0M | 29.0M | 6.0M | 5.0M |
| Cost and Expenses | 20.5M | 24.1M | 29.1M | 26.7M | 14.1M |
| Operating Income (EBIT) | (20.5M) | (21.6M) | (25.1M) | (26.7M) | (14.0M) |
| Non-Operating | |||||
| Interest Income | 104.1K | 174.3K | 173.4K | 776.2K | 7.4K |
| Interest Expense | — | — | 21.4K | — | — |
| Net Interest Income | 104.1K | 174.3K | 152.0K | 776.2K | 7.4K |
| Other Non-Op Income/Expense | 104.1K | 174.3K | 152.0K | 776.2K | 7.4K |
| Non-Operating Income (excl Interest) | 85.7K | (174.3K) | (173.4K) | (776.2K) | (7.4K) |
| EBT (Pre-Tax Income) | (20.4M) | (21.5M) | (25.0M) | (26.0M) | (14.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (20.4M) | (21.5M) | (25.0M) | (26.0M) | (14.0M) |
| Earnings from Cont. Ops | (20.4M) | (21.5M) | (25.0M) | (26.0M) | (14.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (20.4M) | (21.5M) | (25.0M) | (26.0M) | (14.0M) |
| Per Share | |||||
| Basic EPS | ($13.89) | ($22.40) | ($120.50) | ($255.50) | ($138.00) |
| Diluted EPS | ($13.89) | ($22.40) | ($120.50) | ($255.50) | ($138.00) |
| Revenue Per Share | $0.00 | $2.60 | $19.06 | $0.00 | $0.80 |
| Shares | |||||
| Basic Shares Outstanding | 4.6M | 958443 | 207482 | 101595 | 101595 |
| Diluted Shares Outstanding | 4.6M | 958443 | 207482 | 101595 | 101595 |
| Profitability Metrics | |||||
| EBITDA | (20.6M) | (21.4M) | (24.9M) | (25.9M) | (14.0M) |
| D&A | 59.2K | 68.8K | 95.4K | 74.2K | 56.3K |
| EBIT | (20.6M) | (21.5M) | (25.0M) | (26.0M) | (14.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026